大剂量阿糖胞苷治疗急性髓系白血病的远期疗效观察

Long-term therapeutic effect of high-dose Ara-C based protocols on acute myeloblastic leukemia

目的:探讨应用大剂量阿糖胞苷(HD-AraC)治疗急性髓细胞白血病(AML)的疗效及安全性。方法:采用回顾性分析方法,对初次治疗完全缓解的AM L患者给予4个大剂量阿糖胞苷强化化疗,治疗后对长期存活者进行随访观察。结果:58例初治患者中5年以上无病生存率为75.9%(44/58)。HD-AraC匀速静滴120 min时,血液和脑脊液中的AraC和AraU浓度明显升高。结论:大剂量阿糖胞苷强化化疗安全有效,是AML患者获得长期无病生存的重要治疗方法。

Objective： To explore the efficacy and safety of high-dose AraC on acute myeloid leukemia（AML）.Methods： Retrospective analysis was conducted to investigate the long-term survival status of AML patients that were treated with high-dose cytarabine strengthened chemotherapy for 4 courses after complete remission due to initial treatment.Results： Of the fifty-eight patients,44 cases（75.9%） got disease free survival for 5 years or longer.The blood and cerebrospinal fluid concentrations of AraC and AraU significantly increased when patients were given HD-AraC for120 min via intravenous drip. Conclusions： High-dose AraC is a safe and effective therapy for patients with AMLtoget along-termdisease-free survival.